Teacher Retirement System of Texas Purchases 5,250 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

Teacher Retirement System of Texas boosted its position in MiMedx Group, Inc. (NASDAQ:MDXG) by 17.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 34,862 shares of the company’s stock after purchasing an additional 5,250 shares during the quarter. Teacher Retirement System of Texas’ holdings in MiMedx Group were worth $335,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Jane Street Group LLC lifted its holdings in shares of MiMedx Group by 133.6% during the third quarter. Jane Street Group LLC now owns 305,652 shares of the company’s stock worth $1,806,000 after buying an additional 174,797 shares in the last quarter. JPMorgan Chase & Co. raised its stake in MiMedx Group by 265.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company’s stock worth $1,757,000 after purchasing an additional 215,995 shares in the last quarter. Barclays PLC boosted its holdings in MiMedx Group by 163.9% in the 3rd quarter. Barclays PLC now owns 262,449 shares of the company’s stock valued at $1,550,000 after purchasing an additional 163,005 shares during the period. SG Americas Securities LLC boosted its holdings in MiMedx Group by 79.9% in the 4th quarter. SG Americas Securities LLC now owns 83,385 shares of the company’s stock valued at $802,000 after purchasing an additional 37,031 shares during the period. Finally, Principal Financial Group Inc. grew its position in shares of MiMedx Group by 6.3% during the 3rd quarter. Principal Financial Group Inc. now owns 55,495 shares of the company’s stock worth $328,000 after purchasing an additional 3,292 shares in the last quarter. 79.15% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 price target on shares of MiMedx Group in a research report on Thursday, February 27th.

Insider Activity at MiMedx Group

In related news, CAO William Frank Iv Hulse sold 54,596 shares of the company’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $430,762.44. Following the completion of the sale, the chief accounting officer now directly owns 440,178 shares in the company, valued at $3,473,004.42. This represents a 11.03 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Kimberly Maersk-Moller sold 4,106 shares of MiMedx Group stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $32,396.34. Following the completion of the transaction, the insider now owns 310,836 shares in the company, valued at approximately $2,452,496.04. This represents a 1.30 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 144,018 shares of company stock valued at $1,130,312 over the last three months. 1.30% of the stock is owned by insiders.

MiMedx Group Stock Down 1.3 %

Shares of NASDAQ MDXG opened at $7.50 on Wednesday. The stock has a market capitalization of $1.11 billion, a P/E ratio of 13.64 and a beta of 1.97. The stock’s fifty day moving average is $8.20 and its 200 day moving average is $7.94. MiMedx Group, Inc. has a 52 week low of $5.47 and a 52 week high of $10.14. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10.

MiMedx Group (NASDAQ:MDXG) last released its earnings results on Wednesday, February 26th. The company reported $0.07 EPS for the quarter, meeting the consensus estimate of $0.07. The firm had revenue of $92.91 million for the quarter, compared to analyst estimates of $89.42 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. Sell-side analysts forecast that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.